|
Allakos Inc. (Allk) Valoración de DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Allakos Inc. (ALLK) Bundle
¡Descubra el verdadero potencial de Allakos Inc. (Allk) con nuestra calculadora DCF avanzada! Ajuste los supuestos esenciales, explore varios escenarios y evalúe cómo los cambios afectan la valoración de Allakos Inc. (Allk), todo dentro de una plantilla de Excel conveniente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -91.4 | -155.5 | -269.2 | -315.4 | -189.9 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.5 | 2.3 | 4.9 | 10.0 | 6.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -92.9 | -157.9 | -274.0 | -325.3 | -196.1 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 495.9 | 659.0 | 424.2 | 279.8 | 170.8 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 6.0 | 14.0 | 13.7 | 4.8 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.8 | -.6 | -33.2 | -8.3 | -.6 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -84.5 | -151.8 | -271.3 | -322.8 | -196.1 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -77.8 | -142.1 | -299.9 | -330.0 | -193.6 | -1.8 | .0 | .0 | .0 | .0 |
| WACC, % | 7.88 | 7.94 | 7.97 | 7.98 | 7.98 | 7.95 | 7.95 | 7.95 | 7.95 | 7.95 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -25 | |||||||||
| Equity Value | 23 | |||||||||
| Diluted Shares Outstanding, MM | 87 | |||||||||
| Equity Value Per Share | 0.27 |
What You Will Receive
- Comprehensive Financial Model: Allakos Inc.’s actual data provides accurate DCF valuation.
- Complete Forecast Flexibility: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you adjust inputs.
- Professional-Grade Template: A polished Excel file crafted for high-standard valuation purposes.
- Adaptable and Reusable: Designed for versatility, enabling repeated application for thorough forecasts.
Key Features
- Customizable Forecast Inputs: Adjust essential parameters such as revenue projections, operating margins, and research & development expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, net present value, and additional metrics with ease.
- High-Precision Accuracy: Leverages Allakos Inc.'s (ALLK) actual financial data for dependable valuation results.
- Effortless Scenario Analysis: Explore various assumptions and evaluate results effortlessly.
- Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Allakos Inc. (ALLK) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Allakos Inc. (ALLK)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose Allakos Inc. (ALLK)?
- Innovative Solutions: Cutting-edge therapies aimed at addressing significant unmet medical needs.
- Robust Research: Backed by extensive clinical trials and scientific evidence to support efficacy.
- Patient-Centric Approach: Focused on improving the quality of life for patients through targeted treatments.
- Experienced Team: Led by industry experts with a proven track record in biopharmaceutical development.
- Commitment to Quality: Adherence to the highest standards in research and manufacturing processes.
Who Should Use This Product?
- Investors: Evaluate Allakos Inc.’s (ALLK) valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Understand the valuation strategies applied to biotech companies like Allakos Inc.
- Consultants: Provide detailed valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize current market data to study and teach valuation principles.
What the Template Contains
- Pre-Filled Data: Contains Allakos Inc.’s historical financials and projections.
- Discounted Cash Flow Model: Editable DCF valuation model featuring automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC based on user-defined inputs.
- Key Financial Ratios: Assess Allakos Inc.’s profitability, efficiency, and leverage metrics.
- Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation outcomes.